Emerging role of MYB transcription factors in cancer drug resistance

Abstract

Decades ago, the viral myeloblastosis oncogene v-myb was identified as a gene responsible for the development of avian leukemia. However, the relevance of MYB proteins for human cancer diseases, in particular for solid tumors, remained basically unrecognized for a very long time. The human family of MYB transcription factors comprises MYB (c-MYB), MYBL2 (b-MYB), and MYBL1 (a-MYB), which are overexpressed in several cancers and are associated with cancer progression and resistance to anticancer drugs. In addition to overexpression, the presence of activated MYB-fusion proteins as tumor drivers was described in certain cancers. The identification of anticancer drug resistance mediated by MYB proteins and their underlying mechanisms are of great importance in understanding failures of current therapies and establishing new and more efficient therapy regimens. In addition, new drug candidates targeting MYB transcription factor activity and signaling have emerged as a promising class of potential anticancer therapeutics that could tackle MYB-dependent drug-resistant cancers in a more selective way. This review describes the correlation of MYB transcription factors with the formation and persistence of cancer resistance to various approved and investigational anticancer drugs.

Keywords

Anticancer drugs / MYB / transcription factors / oncogenes / drug resistance / cancer resistance mechanisms / MYB-targeting drugs

References

[1] Gottesman MM,Ambudkar SV.New mechanisms of multidrug resistance: an introduction to the cancer drug resistance special collection.Cancer Drug Resist2023;6:590-5 PMCID:PMC10571052

[2] Bushweller JH.Targeting transcription factors in cancer - from undruggable to reality.Nat Rev Cancer2019;19:611-24 PMCID:PMC8820243

[3] Vervoort SJ,Kwiatkowski N,Gray NS.Targeting transcription cycles in cancer.Nat Rev Cancer2022;22:5-24

[4] Chen B,Yang C,Horst D.Targeting non-coding RNAs to overcome cancer therapy resistance.Signal Transduct Target Ther2022;7:121 PMCID:PMC9008121

[5] Planey SL,Arnott JA.Post-translational modification of transcription factors: mechanisms and potential therapeutic interventions.Curr Mol Pharmacol2013;6:173-82

[6] Vishnoi K,Rana A.Transcription factors in cancer development and therapy.Cancers2020;12:2296 PMCID:PMC7464564

[7] Martínez-Martín S.MYC inhibitors in multiple myeloma.Cancer Drug Resist2021;4:842-65 PMCID:PMC8992455

[8] Martínez-Martín S,Soucek L.Targeting MYC-driven lymphoma: lessons learned and future directions.Cancer Drug Resist2023;6:205-22 PMCID:PMC10344726

[9] Singleton KR,Tsui E.Melanoma therapeutic strategies that select against resistance by exploiting MYC-driven evolutionary convergence.Cell Rep2017;21:2796-812 PMCID:PMC5728698

[10] Cicirò Y.MYB oncoproteins: emerging players and potential therapeutic targets in human cancer.Oncogenesis2021;10:19 PMCID:PMC7910556

[11] Anand S,Sudan SK.From modulation of cellular plasticity to potentiation of therapeutic resistance: new and emerging roles of MYB transcription factors in human malignancies.Cancer Metastasis Rev2024;43:409-21 PMCID:PMC11015973

[12] Nakagoshi H,Sawazaki T,Ishii S.Transcriptional activation of the c-myc gene by the c-myb and B-myb gene products.Oncogene1992;7:1233-40

[13] Duesberg PH,Moscovici C.Genetic structure of avian myeloblastosis virus, released from transformed myeloblasts as a defective virus particle.Proc Natl Acad Sci USA1980;77:5120-4 PMCID:PMC350008

[14] Klempnauer KH,Bishop JM.The product of the retroviral transforming gene v-myb is a truncated version of the protein encoded by the cellular oncogene c-myb.Cell1983;33:345-55

[15] Davidson CJ,Lipsick JS.Duplication and maintenance of the Myb genes of vertebrate animals.Biol Open2013;2:101-10 PMCID:PMC3575645

[16] Lipsick JS,Mitiku N,Fogarty P.Functional evolution of the Myb oncogene family.Blood Cells Mol Dis2001;27:456-8

[17] Ogata K,Aimoto S.Solution structure of a DNA-binding unit of Myb: a helix-turn-helix-related motif with conserved tryptophans forming a hydrophobic core.Proc Natl Acad Sci U S A1992;89:6428-32 PMCID:PMC49514

[18] Biedenkapp H,Sippel AE.Viral myb oncogene encodes a sequence-specific DNA-binding activity.Nature1988;335:835-7

[19] Quintana AM,O’Rourke JP.Identification and regulation of c-Myb target genes in MCF-7 cells.BMC Cancer2011;11:30 PMCID:PMC3038977

[20] George OL.Situational awareness: regulation of the myb transcription factor in differentiation, the cell cycle and oncogenesis.Cancers2014;6:2049-71 PMCID:PMC4276956

[21] Ness SA.Myb binding proteins: regulators and cohorts in transformation.Oncogene1999;18:3039-46

[22] Jin Y,Chen G,Fan X.Association between B-Myb proto-oncogene and the development of malignant tumors.Oncol Lett2021;21:166 PMCID:PMC7798104

[23] Anand S,Zubair H.MYB sustains hypoxic survival of pancreatic cancer cells by facilitating metabolic reprogramming.EMBO Rep2023;24:e55643 PMCID:PMC9986821

[24] Okumura F,Nakatsukasa K.Hypoxia-inducible factor-2α stabilizes the von Hippel-Lindau (VHL) disease suppressor, Myb-related protein 2.PLoS One2017;12:e0175593 PMCID:PMC5386292

[25] Zhang Q.The roles of VHL-dependent ubiquitination in signaling and cancer.Front Oncol2012;2:35 PMCID:PMC3355907

[26] Felipe-Abrio B,Carnero A.c-MYB- and PGC1a-dependent metabolic switch induced by MYBBP1A loss in renal cancer.Mol Oncol2019;13:1519-33 PMCID:PMC6599841

[27] Felipe-Abrio B.The tumor suppressor roles of MYBBP1A, a major contributor to metabolism plasticity and stemness.Cancers2020;12:254 PMCID:PMC7017249

[28] Liu M,Mao G,Zhang F.MYB proto-oncogene like 2 promotes hepatocellular carcinoma growth and glycolysis via binding to the Optic atrophy 3 promoter and activating its expression.Bioengineered2022;13:5344-56 PMCID:PMC8973866

[29] Yamauchi T,Nomura T.A B-Myb complex containing clathrin and filamin is required for mitotic spindle function.EMBO J2008;27:1852-62 PMCID:PMC2486420

[30] Sahara S,Nör JE.Systemic therapies for salivary gland adenoid cystic carcinoma.Am J Cancer Res2021;11:4092-110 PMCID:PMC8493384

[31] DeVita VT Jr.A history of cancer chemotherapy.Cancer Res2008;68:8643-53

[32] Sharma I,Tomer R,Sobti RC.History, evolution, milestones in cancer research and treatment. In: Sobti RC, Ganguly NK, Kumar R, editors. Handbook of oncobiology: from basic to clinical sciences. Singapore: Springer; 2023. pp. 1-29.

[33] Vasan N,Hyman DM.A view on drug resistance in cancer.Nature2019;575:299-309 PMCID:PMC8008476

[34] Dilruba S.Platinum-based drugs: past, present and future.Cancer Chemother Pharmacol2016;77:1103-24

[35] Rescigno P,Palmieri G.Platinum drug sensitivity and resistance in testicular germ cell tumors: two sides of the same coin.Cancer Drug Resist2020;3:672-5 PMCID:PMC8992492

[36] Perego P.Tackling cisplatin resistance in ovarian cancer: what can we do?.Cancer Drug Resist2021;4:755-7 PMCID:PMC8992457

[37] Funato T,Kozawa K,Miura T.Use of c-myb antisense oligonucleotides to increase the sensitivity of human colon cancer cells to cisplatin.Oncol Rep2001;8:807-10

[38] Miree O,Khan MA.Clinicopathologic significance and race-specific prognostic association of MYB overexpression in ovarian cancer.Sci Rep2021;11:12901 PMCID:PMC8213794

[39] Tian M,Qiao X,Zhang L.Modulation of Myb-induced NF-kB -STAT3 signaling and resulting cisplatin resistance in ovarian cancer by dietary factors.J Cell Physiol2019;234:21126-34

[40] Xue Y,Sheng Y,Hu B.MicroRNA-1252-5p, regulated by Myb, inhibits invasion and epithelial-mesenchymal transition of pancreatic cancer cells by targeting NEDD9.Aging2021;13:18924-45 PMCID:PMC8351675

[41] Wang Y,Xia RH.The MYB/miR-130a/NDRG2 axis modulates tumor proliferation and metastatic potential in salivary adenoid cystic carcinoma.Cell Death Dis2018;9:917 PMCID:PMC6134089

[42] Liu W,Shao B.STAT3 promotes migration and invasion of cholangiocarcinoma arising from choledochal cyst by transcriptionally inhibiting miR200c through the c-myb/MEK/ERK signaling pathway.Cell Mol Biol2023;69:136-42

[43] Dúcka M,Trčka F.c-Myb interferes with inflammatory IL1α-NF-κB pathway in breast cancer cells.Neoplasia2021;23:326-36 PMCID:PMC7905261

[44] Zhang XY,Ma H.Regulation of MYB mediated cisplatin resistance of ovarian cancer cells involves miR-21-wnt signaling axis.Sci Rep2020;10:6893 PMCID:PMC7181810

[45] Zhou X,Deng G.lncRNA LOC102724169 plus cisplatin exhibit the synergistic anti-tumor effect in ovarian cancer with chronic stress.Mol Ther Nucleic Acids2021;24:294-309 PMCID:PMC8010577

[46] Bu C,Han Y.c-Myb protects cochlear hair cells from cisplatin-induced damage via the PI3K/Akt signaling pathway.Cell Death Discov2022;8:78 PMCID:PMC8873213

[47] Warner KA,Pearson AT.UM-HACC-2A: MYB-NFIB fusion-positive human adenoid cystic carcinoma cell line.Oral Oncol2018;87:21-8 PMCID:PMC6294471

[48] Long J,Tian T.Activation of UBEC2 by transcription factor MYBL2 affects DNA damage and promotes gastric cancer progression and cisplatin resistance.Open Med2023;18:20230757 PMCID:PMC10571520

[49] Guan X,Zhu K.MYSM1 induces apoptosis and sensitizes TNBC cells to cisplatin via RSK3-phospho-BAD pathway.Cell Death Discov2022;8:84 PMCID:PMC8881619

[50] Niklaus NJ,Tschan MP.Cisplatin sensitivity in breast cancer cells is associated with particular DMTF1 splice variant expression.Biochem Biophys Res Commun2018;503:2800-6

[51] MacDonald J,Perampalam P,DiMattia GE.A systematic analysis of negative growth control implicates the DREAM complex in cancer cell dormancy.Mol Cancer Res2017;15:371-81

[52] Sampurno S,Cheasley D.The Myb-p300-CREB axis modulates intestine homeostasis, radiosensitivity and tumorigenesis.Cell Death Dis2013;4:e605 PMCID:PMC3641342

[53] Liu F,Cao Y.Transcription factor B-MYB activates lncRNA CCAT1 and upregulates SOCS3 to promote chemoresistance in colorectal cancer.Chem Biol Interact2023;374:110412

[54] Kadioglu O,Mahmoud N.Identification of potential novel drug resistance mechanisms by genomic and transcriptomic profiling of colon cancer cells with p53 deletion.Arch Toxicol2021;95:959-74 PMCID:PMC7904745

[55] Pekarčíková L,Beneš P.c-Myb regulates NOX1/p38 to control survival of colorectal carcinoma cells.Cell Signal2016;28:924-36

[56] Mattioli R,Colotti B,Fazi F.Doxorubicin and other anthracyclines in cancers: activity, chemoresistance and its overcoming.Mol Aspects Med2023;93:101205

[57] Melani C,Parmiani G,Colombo MP.Inhibition of proliferation by c-myb antisense oligodeoxynucleotides in colon adenocarcinoma cell lines that express c-myb.Cancer Res1991;51:2897-901

[58] Sarvaiya PJ,Hernandez CP,Vedeckis WV.Role of c-Myb in the survival of pre B-cell acute lymphoblastic leukemia and leukemogenesis.Am J Hematol2012;87:969-76 PMCID:PMC3578739

[59] Elcheva IA,Chiarolanzio K.RNA-binding protein IGF2BP1 maintains leukemia stem cell properties by regulating HOXB4, MYB, and ALDH1A1.Leukemia2020;34:1354-63 PMCID:PMC7196026

[60] Říhová K,Zambo IS.Transcription factor c-Myb: novel prognostic factor in osteosarcoma.Clin Exp Metastasis2022;39:375-90

[61] Thorner AR,Parker JS,Millikan RC.In vitro and in vivo analysis of B-Myb in basal-like breast cancer.Oncogene2009;28:742-51 PMCID:PMC2636852

[62] Grassilli E,Perrotti D,Calabretta B.Resistance to apoptosis in CTLL-2 cells overexpressing B-Myb is associated with B-Myb-dependent bcl-2 induction.Cancer Res1999;59:2451-6

[63] Inoue K.Tumor suppression by the EGR1, DMP1, ARF, p53, and PTEN Network.Cancer Invest2018;36:520-36 PMCID:PMC6500763

[64] Taneja P,Matise LA,Choudhary M.Repression of Dmp1 and Arf transcription by anthracyclins: critical roles of the NF-kappaB subunit p65.Oncogene2007;26:7457-66 PMCID:PMC2094103

[65] Montecucco A,Biamonti G.Molecular mechanisms of etoposide.EXCLI J2015;14:95-108 PMCID:PMC4652635

[66] Lotz C.The interplay between DNA topoisomerase 2α post-translational modifications and drug resistance.Cancer Drug Resist2020;3:149-60 PMCID:PMC9090595

[67] Tanno B,Cesi V.Expression of Slug is regulated by c-Myb and is required for invasion and bone marrow homing of cancer cells of different origin.J Biol Chem2010;285:29434-45 PMCID:PMC2937976

[68] Levenson VV,Roninson IB.Pleiotropic resistance to DNA-interactive drugs is associated with increased expression of genes involved in DNA replication, repair, and stress response.Cancer Res2000;60:5027-30

[69] Singh N,Hennis L.Mechanisms of temozolomide resistance in glioblastoma - a comprehensive review.Cancer Drug Resist2021;4:17-43 PMCID:PMC8319838

[70] Siebzehnrubl FA,Tugertimur B.The ZEB1 pathway links glioblastoma initiation, invasion and chemoresistance.EMBO Mol Med2013;5:1196-212 PMCID:PMC3944461

[71] Pieraccioli M,Antonov A,Raschellà G.Activation of miR200 by c-Myb depends on ZEB1 expression and miR200 promoter methylation.Cell Cycle2013;12:2309-20 PMCID:PMC3755081

[72] Hugo HJ,Suryadinata R.Direct repression of MYB by ZEB1 suppresses proliferation and epithelial gene expression during epithelial-to-mesenchymal transition of breast cancer cells.Breast Cancer Res2013;15:R113 PMCID:PMC3979034

[73] Bhise NS,Shin M.MicroRNA-mRNA pairs associated with outcome in AML: from in vitro cell-based studies to AML patients.Front Pharmacol2015;6:324 PMCID:PMC4729948

[74] Paik J.Olaparib: A review as first-line maintenance therapy in advanced ovarian cancer.Target Oncol2021;16:847-56

[75] Qi G,Ma H.CDCA8, targeted by MYBL2, promotes malignant progression and olaparib insensitivity in ovarian cancer.Am J Cancer Res2021;11:389-415 PMCID:PMC7868764

[76] Li L,Yang G.Targeting poly(ADP-ribose) polymerase and the c-Myb-regulated DNA damage response pathway in castration-resistant prostate cancer.Sci Signal2014;7:ra47 PMCID:PMC4135429

[77] Murray V,Chung LH.The interaction of the metallo-glycopeptide anti-tumour drug bleomycin with DNA.Int J Mol Sci2018;19:1372 PMCID:PMC5983701

[78] Robertson KA,Xu Y.Altered expression of Ape1/ref-1 in germ cell tumors and overexpression in NT2 cells confers resistance to bleomycin and radiation.Cancer Res2001;61:2220-5

[79] Kim TE.Recent studies in photodynamic therapy for cancer treatment: from basic research to clinical trials.Pharmaceutics2023;15:2257 PMCID:PMC10535460

[80] Hui YJ,Peng XC.Up-regulation of ABCG2 by MYBL2 deletion drives chlorin e6-mediated photodynamic therapy resistance in colorectal cancer.Photodiagnosis Photodyn Ther2023;42:103558

[81] Mo W.Human ABCG2: structure, function, and its role in multidrug resistance.Int J Biochem Mol Biol2012;3:1-27 PMCID:PMC3325772

[82] Škubník J,Ruml T.Vincristine in combination therapy of cancer: emerging trends in clinics.Biology2021;10:849 PMCID:PMC8468923

[83] Chen L,Wang J.[Spectrum of gene expression of a multi-drug resistant leukemia cell line with high tumorigenecity in nude mice].Zhonghua Zhong Liu Za Zhi2005;27:196-200. (in Chinese)

[84] Mosca L,Fazi F,Colotti G.Taxanes in cancer treatment: activity, chemoresistance and its overcoming.Drug Resist Updat2021;54:100742

[85] Chen L,Hou T.Circ_0004087 interaction with SND1 promotes docetaxel resistance in prostate cancer by boosting the mitosis error correction mechanism.J Exp Clin Cancer Res2022;41:194 PMCID:PMC9166435

[86] Wei Y,Wei J,Qin Y.Identification and verification of microtubule associated genes in lung adenocarcinoma.Sci Rep2023;13:16134 PMCID:PMC10522656

[87] Hunsu VO,Fields JZ.Retinoids as chemo-preventive and molecular-targeted anti-cancer therapies.Int J Mol Sci2021;22:7731 PMCID:PMC8304138

[88] Smarda J,Bryja J.Retinoid X receptor suppresses transformation by the v-myb oncogene.J Leukoc Biol1999;66:1039-48

[89] Benes P,Zatloukalová J,Smardová J.Retinoic acid enhances differentiation of v-myb-transformed monoblasts induced by okadaic acid.Leuk Res2007;31:1421-31

[90] Trčka F,Knopfová L,Beneš P.Nuclear factor of activated T-cells 1 increases sensitivity of v-myb transformed monoblasts to all-trans retinoic acid.Cell Signal2013;25:1546-55

[91] Cesi V,Vitali R.Cyclin D1-dependent regulation of B-myb activity in early stages of neuroblastoma differentiation.Cell Death Differ2002;9:1232-9

[92] Olivas-Aguirre M,Pottosin I.Overcoming glucocorticoid resistance in acute lymphoblastic leukemia: repurposed drugs can improve the protocol.Front Oncol2021;11:617937 PMCID:PMC7991804

[93] Jing D,Beck D.Opposing regulation of BIM and BCL2 controls glucocorticoid-induced apoptosis of pediatric acute lymphoblastic leukemia cells.Blood2015;125:273-83

[94] Salomoni P,Martinez R,Calabretta B.Resistance to apoptosis in CTLL-2 cells constitutively expressing c-Myb is associated with induction of BCL-2 expression and Myb-dependent regulation of the bcl-2 promoter activity.Proc Natl Acad Sci USA1997;94:3296-301 PMCID:PMC20363

[95] Geng CD.Use of recombinant cell-permeable small peptides to modulate glucocorticoid sensitivity of acute lymphoblastic leukemia cells.Biochemistry2010;49:8892-901 PMCID:PMC2953583

[96] Kfir-Erenfeld S,Biton M,Assayag-Asherie N.miR-103 inhibits proliferation and sensitizes hemopoietic tumor cells for glucocorticoid-induced apoptosis.Oncotarget2017;8:472-89 PMCID:PMC5352135

[97] Drabsch Y,Zhang R.Mechanism of and requirement for estrogen-regulated MYB expression in estrogen-receptor-positive breast cancer cells.Proc Natl Acad Sci U S A2007;104:13762-7 PMCID:PMC1959456

[98] Howell A.Tamoxifen evolution.Br J Cancer2023;128:421-5 PMCID:PMC9938251

[99] Gao Y,Liu C.miR-200 affects tamoxifen resistance in breast cancer cells through regulation of MYB.Sci Rep2019;9:18844 PMCID:PMC6906507

[100] Hodges LC,Lobenhofer EK.Tamoxifen functions as a molecular agonist inducing cell cycle-associated genes in breast cancer cells.Mol Cancer Res2003;1:300-11

[101] Li X,Wu CC.The role of MYB proto-oncogene like 2 in tamoxifen resistance in breast cancer.J Mol Histol2021;52:21-30

[102] Nathan MR.A review of fulvestrant in breast cancer.Oncol Ther2017;5:17-29 PMCID:PMC5488136

[103] Lee J,Wittner BS.Induction of stable drug resistance in human breast cancer cells using a combinatorial zinc finger transcription factor library.PLoS One2011;6:e21112 PMCID:PMC3139592

[104] Edavana VK,Yao-Borengasser A.Fulvestrant up regulates UGT1A4 and MRPs through ERα and c-Myb pathways: a possible primary drug disposition mechanism.Springerplus2013;2:620 PMCID:PMC3841332

[105] Edwards J,Witton CJ.Gene amplifications associated with the development of hormone-resistant prostate cancer.Clin Cancer Res2003;9:5271-81

[106] Thompson TC.New targets for resistant prostate cancer.Oncotarget2014;5:8816-7 PMCID:PMC4253400

[107] Srivastava SK,Singh S.Myb overexpression overrides androgen depletion-induced cell cycle arrest and apoptosis in prostate cancer cells, and confers aggressive malignant traits: potential role in castration resistance.Carcinogenesis2012;33:1149-57 PMCID:PMC3514863

[108] Li Q,Hu Y.MYBL2 disrupts the Hippo-YAP pathway and confers castration resistance and metastatic potential in prostate cancer.Theranostics2021;11:5794-812 PMCID:PMC8058714

[109] Srivastava SK,Anand S.MYB interacts with androgen receptor, sustains its ligand-independent activation and promotes castration resistance in prostate cancer.Br J Cancer2022;126:1205-14 PMCID:PMC9023474

[110] de Bono JS, Logothetis CJ, Molina A, et al; COU-AA-301 Investigators. Abiraterone and increased survival in metastatic prostate cancer.N Engl J Med2011;364:1995-2005 PMCID:PMC3471149

[111] Blatti C,Gao H.Bayesian machine learning enables identification of transcriptional network disruptions associated with drug-resistant prostate cancer.Cancer Res2023;83:1361-80 PMCID:PMC10102853

[112] Baudino TA.Targeted cancer therapy: the next generation of cancer treatment.Curr Drug Discov Technol2015;12:3-20

[113] Nepali K.Recent developments in epigenetic cancer therapeutics: clinical advancement and emerging trends.J Biomed Sci2021;28:27 PMCID:PMC8040241

[114] Waldman AD,Lenardo MJ.A guide to cancer immunotherapy: from T cell basic science to clinical practice.Nat Rev Immunol2020;20:651-68 PMCID:PMC7238960

[115] Steins M,Geißler M.Erlotinib. In: Martens U, editor. Small molecules in oncology. Recent Results in Cancer Research. Cham: Springer; 2018. pp. 1-17.

[116] García-Foncillas J,Aderka D.Distinguishing features of cetuximab and panitumumab in colorectal cancer and other solid tumors.Front Oncol2019;9:849 PMCID:PMC6763619

[117] Liang L,Sun X.Identification of key genes involved in tumor immune cell infiltration and cetuximab resistance in colorectal cancer.Cancer Cell Int2021;21:135 PMCID:PMC7905896

[118] Iida M,Campbell DA,Wheeler DL.Yes and Lyn play a role in nuclear translocation of the epidermal growth factor receptor.Oncogene2013;32:759-67 PMCID:PMC3381861

[119] Garnock-Jones KP,Scott LJ.Trastuzumab: a review of its use as adjuvant treatment in human epidermal growth factor receptor 2 (HER2)-positive early breast cancer.Drugs2010;70:215-39

[120] Rezaei Z,Allahyari A.Plasma microRNA-195, -34c, and -1246 as novel biomarkers for the diagnosis of trastuzumab-resistant HER2-positive breast cancer patients.Toxicol Appl Pharmacol2023;475:116652

[121] Iyer R,Lugade A.Sorafenib: a clinical and pharmacologic review.Expert Opin Pharmacother2010;11:1943-55

[122] Zhu J,Yu Y,Shen J.MYBL1 induces transcriptional activation of ANGPT2 to promote tumor angiogenesis and confer sorafenib resistance in human hepatocellular carcinoma.Cell Death Dis2022;13:727 PMCID:PMC9392790

[123] Okumura F,Byrne SD.Parallel regulation of von hippel-lindau disease by pVHL-mediated degradation of B-Myb and hypoxia-inducible factor α.Mol Cell Biol2016;36:1803-17 PMCID:PMC4907096

[124] Kanei-Ishii C,Takagi T,Nakayama KI.Fbxw7 acts as an E3 ubiquitin ligase that targets c-Myb for nemo-like kinase (NLK)-induced degradation.J Biol Chem2008;283:30540-8 PMCID:PMC2662147

[125] Iqbal N.Imatinib: a breakthrough of targeted therapy in cancer.Chemother Res Pract2014;2014:357027 PMCID:PMC4055302

[126] Ohmine K,Tarumoto T.Analysis of gene expression profiles in an imatinib-resistant cell line, KCL22/SR.Stem Cells2003;21:315-21

[127] Corradini F,Bartella V.Enhanced proliferative potential of hematopoietic cells expressing degradation-resistant c-Myb mutants.J Biol Chem2005;280:30254-62

[128] Corradini F,Cerioli D,Calabretta B.A degradation-resistant c-Myb mutant cooperates with Bcl-2 in enhancing proliferative potential and survival of hematopoietic cells.Blood Cells Mol Dis2007;39:292-6 PMCID:PMC4274770

[129] Cofre J,Pizzatti L.Knock-down of Kaiso induces proliferation and blocks granulocytic differentiation in blast crisis of chronic myeloid leukemia.Cancer Cell Int2012;12:28 PMCID:PMC3461418

[130] Srutova K,Burda P.BCR-ABL1 mediated miR-150 downregulation through MYC contributed to myeloid differentiation block and drug resistance in chronic myeloid leukemia.Haematologica2018;103:2016-25 PMCID:PMC6269310

[131] Fehr A,Nordlund J,Stenman G.Increased MYB alternative promoter usage is associated with relapse in acute lymphoblastic leukemia.Genes Chromosomes Cancer2023;62:597-606

[132] Horwitz SM,Hess BT.The novel SYK/JAK inhibitor cerdulatinib demonstrates good tolerability and clinical response in a phase 2a study in relapsed/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma.Blood2018;132:1001

[133] Tavakoli Shirazi P, Eadie LN, Page EC, Heatley SL, Bruning JB, White DL. Constitutive JAK/STAT signaling is the primary mechanism of resistance to JAKi in TYK2-rearranged acute lymphoblastic leukemia.Cancer Lett2021;512:28-37

[134] Angius G,Stati V,Bianco V.Prexasertib, a checkpoint kinase inhibitor: from preclinical data to clinical development.Cancer Chemother Pharmacol2020;85:9-20

[135] Branigan TB,Schade AE.MMB-FOXM1-driven premature mitosis is required for CHK1 inhibitor sensitivity.Cell Rep2021;34:108808 PMCID:PMC7970065

[136] Chambers AE,Chaplin T.Histone acetylation-mediated regulation of genes in leukaemic cells.Eur J Cancer2003;39:1165-75

[137] Drabsch Y,Gonda TJ.MYB suppresses differentiation and apoptosis of human breast cancer cells.Breast Cancer Res2010;12:R55 PMCID:PMC2949644

[138] Marks PA.Discovery and development of SAHA as an anticancer agent.Oncogene2007;26:1351-6

[139] Peart MJ,van Laar RK.Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors.Proc Natl Acad Sci U S A2005;102:3697-702 PMCID:PMC552783

[140] Ye P,McGirr C.MYB down-regulation enhances sensitivity of U937 myeloid leukemia cells to the histone deacetylase inhibitor LBH589 in vitro and in vivo.Cancer Lett2014;343:98-106

[141] Esfahani K,Buhlaiga N,Papneja N.A review of cancer immunotherapy: from the past, to the present, to the future.Curr Oncol2020;27:S87-97 PMCID:PMC7194005

[142] Millen R,Cross RS.Immunomodulation by MYB is associated with tumor relapse in patients with early stage colorectal cancer.Oncoimmunology2016;5:e1149667 PMCID:PMC5006930

[143] Pan B,Zhou Y.The MYBL2-CCL2 axis promotes tumor progression and resistance to anti-PD-1 therapy in ovarian cancer by inducing immunosuppressive macrophages.Cancer Cell Int2023;23:248 PMCID:PMC10590509

[144] Citro G,Cucco C.Inhibition of leukemia cell proliferation by receptor-mediated uptake of c-myb antisense oligodeoxynucleotides.Proc Natl Acad Sci U S A1992;89:7031-5 PMCID:PMC49639

[145] Citro G,Ginobbi P,Calabretta B.Inhibition of leukaemia cell proliferation by folic acid-polylysine-mediated introduction of c-myb antisense oligodeoxynucleotides into HL-60 cells.Br J Cancer1994;69:463-7 PMCID:PMC1968841

[146] Del Bufalo D,Leonetti C.Effect of cisplatin and c-myb antisense phosphorothioate oligodeoxynucleotides combination on a human colon carcinoma cell line in vitro and in vivo.Br J Cancer1996;74:387-93 PMCID:PMC2074645

[147] Hu D,Liu L.Intricate crosstalk between MYB and noncoding RNAs in cancer.Cancer Cell Int2021;21:653 PMCID:PMC8650324

[148] Pham T,Sampurno S.Novel vaccine targeting colonic adenoma: a pre-clinical model.J Gastrointest Surg2019;23:626-33

[149] Cross RS,Davenport AJ.Therapeutic DNA vaccination against colorectal cancer by targeting the MYB oncoprotein.Clin Transl Immunology2015;4:e30 PMCID:PMC4318491

[150] Pham T,Roth S.First-in-human phase I clinical trial of a combined immune modulatory approach using TetMYB vaccine and Anti-PD-1 antibody in patients with advanced solid cancer including colorectal or adenoid cystic carcinoma: The MYPHISMO study protocol (NCT03287427).Contemp Clin Trials Commun2019;16:100409 PMCID:PMC6804811

[151] Mahmood U,Chen YH.A randomized phase 2 study of pembrolizumab with or without radiation in patients with recurrent or metastatic adenoid cystic carcinoma.Int J Radiat Oncol Biol Phys2021;109:134-44 PMCID:PMC9361179

[152] Cleymaet R,Coopman R,De Keukeleire S.The therapeutic landscape of salivary gland malignancies-where are we now?.Int J Mol Sci2022;23:14891 PMCID:PMC9740091

[153] Dillon PM,Horton BJ.A phase II study of dovitinib in patients with recurrent or metastatic adenoid cystic carcinoma.Clin Cancer Res2017;23:4138-45 PMCID:PMC5540767

[154] Tchekmedyian V,Dunn L.Phase II study of lenvatinib in patients with progressive, recurrent or metastatic adenoid cystic carcinoma.J Clin Oncol2019;37:1529-37 PMCID:PMC6599407

[155] Ho AL,Sherman EJ.A phase II study of axitinib (AG-013736) in patients with incurable adenoid cystic carcinoma.Ann Oncol2016;27:1902-8 PMCID:PMC5035791

[156] Locati LD,Cortelazzi B.A phase II study of sorafenib in recurrent and/or metastatic salivary gland carcinomas: Translational analyses and clinical impact.Eur J Cancer2016;69:158-65

[157] Couvreur K,Marlies B.Efficacy and toxicity of sorafenib in patients with adenoid cystic carcinoma of the head and neck: a case series of five patients.Acta Clin Belg2020;75:362-9

[158] Zheng S,Lin Y.Treatment response to eribulin and anlotinib in lung metastases from rare perianal adenoid cystic carcinoma: a case report.Anticancer Drugs2022;33:e548-54 PMCID:PMC8670344

[159] Su N,Wang J.Efficacy and safety of anlotinib in metastatic adenoid cystic carcinoma: a retrospective study.Transl Cancer Res2022;11:2757-66 PMCID:PMC9459595

[160] Hanna GJ,Muzaffar J.A phase II trial of rivoceranib, an oral vascular endothelial growth factor receptor 2 inhibitor, for recurrent or metastatic adenoid cystic carcinoma.Clin Cancer Res2023;29:4555-63 PMCID:PMC10643996

[161] Ono J.Study of MYB-NFIB chimeric gene expression, tumor angiogenesis, and proliferation in adenoid cystic carcinoma of salivary gland.Odontology2018;106:238-44

[162] Chen C,Wangsa D.A multiplex preclinical model for adenoid cystic carcinoma of the salivary gland identifies regorafenib as a potential therapeutic drug.Sci Rep2017;7:11410 PMCID:PMC5595986

[163] Dai YH,Chen RY,Chang KC.ON 01910.Na inhibits growth of diffuse large B-cell lymphoma by cytoplasmic sequestration of sumoylated C-MYB/TRAF6 complex.Transl Res2016;175:129-43.e13

[164] Sun B,Sun J.Establishment of patient-derived xenograft models of adenoid cystic carcinoma to assess pre-clinical efficacy of combination therapy of a PI3K inhibitor and retinoic acid.Am J Cancer Res2021;11:773-92 PMCID:PMC7994170

[165] Ladu S,Conner EA,Factor VM.E2F1 inhibits c-Myc-driven apoptosis via PIK3CA/Akt/mTOR and COX-2 in a mouse model of human liver cancer.Gastroenterology2008;135:1322-32 PMCID:PMC2614075

[166] Hugo HJ,Ramsay RG.New insights on COX-2 in chronic inflammation driving breast cancer growth and metastasis.J Mammary Gland Biol Neoplasia2015;20:109-19

[167] Kim DW,Shin SH.A multicenter phase II study of everolimus in patients with progressive unresectable adenoid cystic carcinoma.BMC Cancer2014;14:795 PMCID:PMC4228069

[168] Harvey RD,Lewis C.Phase 1 safety and pharmacodynamic study of lenalidomide combined with everolimus in patients with advanced solid malignancies with efficacy signal in adenoid cystic carcinoma.Br J Cancer2020;123:1228-34 PMCID:PMC7553949

[169] Zhang X,Huang YT,Zhou HH.Akt/FoxM1 signaling pathway-mediated upregulation of MYBL2 promotes progression of human glioma.J Exp Clin Cancer Res2017;36:105 PMCID:PMC5547476

[170] Biyanee A,Klempnauer KH.Src-family protein kinase inhibitors suppress MYB activity in a p300-dependent manner.Cells2022;11:1162 PMCID:PMC8997952

[171] Murray HC,Brzozowski JS.Synergistic targeting of DNA-PK and KIT signaling pathways in KIT mutant acute myeloid leukemia.Mol Cell Proteomics2023;22:100503 PMCID:PMC9986649

[172] Wong SJ,Hayes DN.Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors.Ann Oncol2016;27:318-23 PMCID:PMC4722891

[173] Matsumura-Kimoto Y,Shimura Y.Serine-227 in the N-terminal kinase domain of RSK2 is a potential therapeutic target for mantle cell lymphoma.Cancer Med2020;9:5185-99 PMCID:PMC7367644

[174] Soncini D,Ruberti S.The new small tyrosine kinase inhibitor ARQ531 targets acute myeloid leukemia cells by disrupting multiple tumor-addicted programs.Haematologica2020;105:2420-31 PMCID:PMC7556675

[175] Shirazi PT,Heatley SL.Exploring the oncogenic and therapeutic target potential of the MYB-TYK2 fusion gene in B-cell acute lymphoblastic leukemia.Cancer Gene Ther2022;29:1140-52

[176] Zhang Y,Zhong H.The JAK2 inhibitor TG101209 exhibits anti-tumor and chemotherapeutic sensitizing effects on Burkitt lymphoma cells by inhibiting the JAK2/STAT3/c-MYB signaling axis.Cell Death Discov2021;7:268 PMCID:PMC8481535

[177] Andersson MK,Nevado PT.ATR is a MYB regulated gene and potential therapeutic target in adenoid cystic carcinoma.Oncogenesis2020;9:5 PMCID:PMC6992744

[178] Zhou F,van Laar T,Ten Dijke P.GSK3β inactivation induces apoptosis of leukemia cells by repressing the function of c-Myb.Mol Biol Cell2011;22:3533-40 PMCID:PMC3172276

[179] Albert V,Yousseff D.Protein kinase C targeting of luminal (T-47D), luminal/HER2-positive (BT474), and triple negative (HCC1806) breast cancer cells in-vitro with AEB071 (Sotrastaurin) is efficient but mediated by subtype specific molecular effects.Arch Gynecol Obstet2022;306:1197-210 PMCID:PMC9470618

[180] Liu W,Huang Z.c-myb hyperactivity leads to myeloid and lymphoid malignancies in zebrafish.Leukemia2017;31:222-33 PMCID:PMC5972522

[181] Ye Y,Li F,Zhang W.c-myb is involved in CML progression and is a therapeutic target in the zebrafish CML model. Animal Model Exp Med 2022;7:136-44.

[182] De Dominici M,Soliera AR.Targeting CDK6 and BCL2 exploits the “MYB addiction” of Ph⁺ acute lymphoblastic leukemia.Cancer Res2018;78:1097-109 PMCID:PMC5815914

[183] Mitra P,Sutton J,Gonda TJ.CDK9 inhibitors selectively target estrogen receptor-positive breast cancer cells through combined inhibition of MYB and MCL-1 expression.Oncotarget2016;7:9069-83 PMCID:PMC4891027

[184] Chen HX.IGF-1R as an anti-cancer target--trials and tribulations.Chin J Cancer2013;32:242-52 PMCID:PMC3845553

[185] Andersson MK,Stenman G.IGF2/IGF1R signaling as a therapeutic target in MYB-positive adenoid cystic carcinomas and other fusion gene-driven tumors.Cells2019;8:913 PMCID:PMC6721700

[186] Andersson MK,Andrén Y,Stenman G.Targeting the oncogenic transcriptional regulator MYB in adenoid cystic carcinoma by inhibition of IGF1R/AKT signaling.J Natl Cancer Inst2017;109:djx017

[187] Pavlicek A,Lee NV.Molecular predictors of sensitivity to the insulin-like growth factor 1 receptor inhibitor Figitumumab (CP-751,871).Mol Cancer Ther2013;12:2929-39

[188] Calvo E,Ma WW.A phase I clinical trial and independent patient-derived xenograft study of combined targeted treatment with dacomitinib and figitumumab in advanced solid tumors.Clin Cancer Res2017;23:1177-85

[189] Parikh AS,Davis D.Single-cell RNA sequencing identifies a paracrine interaction that may drive oncogenic notch signaling in human adenoid cystic carcinoma.Cell Rep2022;41:111743 PMCID:PMC9760094

[190] Eliasz S,Chen Y.Notch-1 stimulates survival of lung adenocarcinoma cells during hypoxia by activating the IGF-1R pathway.Oncogene2010;29:2488-98 PMCID:PMC2861728

[191] Brana I,Golan T.A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours.Br J Cancer2014;111:1932-44 PMCID:PMC4229637

[192] Thompson MA,Ellis SL.c-Myb down-regulation is associated with human colon cell differentiation, apoptosis, and decreased Bcl-2 expression.Cancer Res1998;58:5168-75

[193] Frech M,Feld C.MYB induces the expression of the oncogenic corepressor SKI in acute myeloid leukemia.Oncotarget2018;9:22423-35 PMCID:PMC5976475

[194] Vrana JA,Johnson CR.Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53.Oncogene1999;18:7016-25

[195] Claerhout S,Choi W.Gene expression signature analysis identifies vorinostat as a candidate therapy for gastric cancer.PLoS One2011;6:e24662 PMCID:PMC3170379

[196] Goncalves PH,Barrett MT.A phase 2 study of vorinostat in locally advanced, recurrent, or metastatic adenoid cystic carcinoma.Oncotarget2017;8:32918-29 PMCID:PMC5464838

[197] Calzada A, Todoerti K, Donadoni L, et al; AGIMM Investigators. The HDAC inhibitor Givinostat modulates the hematopoietic transcription factors NFE2 and C-MYB in JAK2(V617F) myeloproliferative neoplasm cells.Exp Hematol2012;40:634-45.e10

[198] Courdy C,Ducau C.Targeting PP2A-dependent autophagy enhances sensitivity to ruxolitinib in JAK2^V617F myeloproliferative neoplasms.Blood Cancer J2023;13:106 PMCID:PMC10330179

[199] Yusenko MV.Characterization of the MYB-inhibitory potential of the Pan-HDAC inhibitor LAQ824.BBA Adv2022;2:100034 PMCID:PMC10074929

[200] Kaundal B,Dev A,Karmakar S.Nanoformulation of EPZ011989 attenuates EZH2-c-Myb epigenetic interaction by proteasomal degradation in acute myeloid leukemia.Mol Pharm2020;17:604-21

[201] Roe JS,Rivera K,Vakoc CR.BET bromodomain inhibition suppresses the function of hematopoietic transcription factors in acute myeloid leukemia.Mol Cell2015;58:1028-39 PMCID:PMC4475489

[202] Bhagwat AS,Mok BYL,Shi J.BET bromodomain inhibition releases the mediator complex from select cis-regulatory elements.Cell Rep2016;15:519-30 PMCID:PMC4838499

[203] Lim SL,Shyamsunder P.Proteolysis targeting chimeric molecules as therapy for multiple myeloma: efficacy, biomarker and drug combinations.Haematologica2019;104:1209-20 PMCID:PMC6545861

[204] Rose AJ,Francis JC.Cell-type-specific tumour sensitivity identified with a bromodomain targeting PROTAC in adenoid cystic carcinoma.J Pathol2024;262:37-49

[205] Liu Q,Huang X.A targetable MYBL2-ATAD2 axis governs cell proliferation in ovarian cancer.Cancer Gene Ther2023;30:192-208

[206] Mandelbaum J,Henderson RE.Zebrafish blastomere screen identifies retinoic acid suppression of MYB in adenoid cystic carcinoma.J Exp Med2018;215:2673-85 PMCID:PMC6170170

[207] Zhou MJ,Ma TY.Increased retinoic acid signaling decreases lung metastasis in salivary adenoid cystic carcinoma by inhibiting the noncanonical Notch1 pathway.Exp Mol Med2023;55:597-611 PMCID:PMC10073150

[208] Hanna GJ,Cutler JM.A phase II trial of all-trans retinoic acid (ATRA) in advanced adenoid cystic carcinoma.Oral Oncol2021;119:105366

[209] Kasukabe T,Hozumi M.Inhibition by interleukin 4 of leukemia inhibitory factor-, interleukin 6-, and dexamethasone-induced differentiation of mouse myeloid leukemia cells: role of c-myc and junB proto-oncogenes.Cancer Res1994;54:592-7

[210] Yang H,Ai Z.MicroRNA-16 regulates myeloblastosis oncogene expression to affect differentiation of acute leukemia cells.Clin Lab2019;65:

[211] Bandyopadhyay A,Dhamija P.Safety and efficacy of Vitamin D₃ supplementation with imatinib in chronic phase- chronic myeloid leukaemia: an exploratory randomized controlled trial.BMJ Open2023;13:e066361 PMCID:PMC10465917

[212] Al-Ali L,Saleh MM.Biological evaluation of combinations of tyrosine kinase inhibitors with Inecalcitol as novel treatments for human chronic myeloid leukemia.Saudi Pharm J2024;32:101931 PMCID:PMC10827560

[213] Wilkins HR,Duke V,Johnson N.Estrogen prevents sustained COLO-205 human colon cancer cell growth by inducing apoptosis, decreasing c-myb protein, and decreasing transcription of the anti-apoptotic protein bcl-2.Tumour Biol2010;31:16-22

[214] Salisbury TB,Tomblin JK,Cook CR.Aryl hydrocarbon receptor ligands inhibit igf-ii and adipokine stimulated breast cancer cell proliferation.ISRN Endocrinol2013;2013:104850 PMCID:PMC3793317

[215] Collins CT.Role of HOXA9 in leukemia: dysregulation, cofactors and essential targets.Oncogene2016;35:1090-8

[216] Sonoda Y,Tohda S.Effects of HOXA9 inhibitor DB818 on the growth of acute myeloid leukaemia cells.Anticancer Res2021;41:1841-7

[217] Gehringer F,Swier LJ,Wirth T.FOXO1 confers maintenance of the dark zone proliferation and survival program and can be pharmacologically targeted in burkitt lymphoma.Cancers2019;11:1427 PMCID:PMC6826697

[218] Zheng L,Tao S.Destabilization of macrophage migration inhibitory factor by 4-IPP reduces NF-κB/P-TEFb complex-mediated c-Myb transcription to suppress osteosarcoma tumourigenesis.Clin Transl Med2022;12:e652 PMCID:PMC8777168

[219] McSheehy PM,Lampasona V,D’Incalci M.Studies of the differentiation properties of camptothecin in the human leukaemic cells K562.Eur J Cancer1991;27:1406-11

[220] Li F,Xu M.Exploration of G-quadruplex function in c-Myb gene and its transcriptional regulation by topotecan.Int J Biol Macromol2018;107:1474-9

[221] Liu Q,Lv C.Brucine inhibits proliferation of glioblastoma cells by targeting the G-quadruplexes in the c-Myb promoter.J Cancer2021;12:1990-9 PMCID:PMC7974541

[222] Zauli G,di Iasio MG.miR-34a induces the downregulation of both E2F1 and B-Myb oncogenes in leukemic cells.Clin Cancer Res2011;17:2712-24

[223] Sottile F,Cantilena S,Sala A.A chemical screen identifies the chemotherapeutic drug topotecan as a specific inhibitor of the B-MYB/MYCN axis in neuroblastoma.Oncotarget2012;3:535-45 PMCID:PMC3388183

[224] Li Y,Zhang W.A novel camptothecin derivative, ZBH-01, exhibits superior antitumor efficacy than irinotecan by regulating the cell cycle.J Transl Med2023;21:422 PMCID:PMC10308760

[225] Okuno K,Yuan YC,Kinugasa Y.Corrigendum: Berberine and oligomeric proanthocyanidins exhibit synergistic efficacy through regulation of PI3K-Akt signaling pathway in colorectal cancer.Front Oncol2022;12:952180 PMCID:PMC9278059

[226] Schmidt TJ.Natural products with antitumor potential targeting the MYB-C/EBPβ-p300 transcription module.Molecules2022;27:2077 PMCID:PMC9000602

[227] Klempnauer KH.Transcription factor MYB as therapeutic target: current developments.Int J Mol Sci2024;25:3231 PMCID:PMC10970396

[228] Uttarkar S,Coulibaly A.Targeting acute myeloid leukemia with a small molecule inhibitor of the Myb/p300 interaction.Blood2016;127:1173-82

[229] Clesham K,Gasparoli L.Identification of a c-MYB-directed therapeutic for acute myeloid leukemia.Leukemia2022;36:1541-9 PMCID:PMC9162920

[230] Tejera Nevado P, Tešan Tomić T, Atefyekta A, Fehr A, Stenman G, Andersson MK. Synthetic oleanane triterpenoids suppress MYB oncogene activity and sensitize T-cell acute lymphoblastic leukemia cells to chemotherapy.Front Oncol2023;13:1126354 PMCID:PMC10106619

[231] Yusenko MV,Andersson MK.Monensin, a novel potent MYB inhibitor, suppresses proliferation of acute myeloid leukemia and adenoid cystic carcinoma cells.Cancer Lett2020;479:61-70

[232] Lee YJ,Lee SY,Han DC.Ginkgetin induces G2-phase arrest in HCT116 colon cancer cells through the modulation of b-Myb and miRNA34a expression.Int J Oncol2017;51:1331-42

[233] Liu XM,Li HY.Induction of differentiation and down-regulation of c-myb gene expression in ML-1 human myeloblastic leukemia cells by the clinically effective anti-leukemia agent meisoindigo.Biochem Pharmacol1996;51:1545-51

[234] Chen F,Ma D.Imatinib achieved complete cytogenetic response in a CML patient received 32-year indirubin and its derivative treatment.Leuk Res2010;34:e75-7

[235] Han SS,Kamberos NL.Piperlongumine inhibits the proliferation and survival of B-cell acute lymphoblastic leukemia cell lines irrespective of glucocorticoid resistance.Biochem Biophys Res Commun2014;452:669-75

[236] Yusenko M,Klempnauer KH.A novel cell-based screening assay for small-molecule MYB inhibitors identifies podophyllotoxins teniposide and etoposide as inhibitors of MYB activity.Sci Rep2018;8:13159 PMCID:PMC6120916

[237] Yusenko MV,Frank D.Bcr-TMP, a novel nanomolar-active compound that exhibits both MYB- and microtubule-inhibitory activity.Cancers2021;14:43 PMCID:PMC8750090

[238] Köhler LHF,Yusenko M.A new naphthopyran derivative combines c-Myb inhibition, microtubule-targeting effects, and antiangiogenic properties.ACS Med Chem Lett2022;13:1783-90 PMCID:PMC9661705

[239] Köhler LHF,Yusenko M.Multimodal 4-arylchromene derivatives with microtubule-destabilizing, anti-angiogenic, and MYB-inhibitory activities.Cancer Drug Resist2023;6:59-77 PMCID:PMC10099595

[240] Uttarkar S,Bopp B,Jose J.Naphthol AS-E phosphate inhibits the activity of the transcription factor Myb by blocking the interaction with the KIX domain of the coactivator p300.Mol Cancer Ther2015;14:1276-85

[241] Ramaswamy K,Minuesa G.Peptidomimetic blockade of MYB in acute myeloid leukemia.Nat Commun2018;9:110 PMCID:PMC5760651

[242] Joy ST,De Salle SN.A dual-site inhibitor of CBP/p300 KIX is a selective and effective modulator of Myb.J Am Chem Soc2021;143:15056-62

[243] Yusenko MV,Andersson MK.Proteasome inhibitors suppress MYB oncogenic activity in a p300-dependent manner.Cancer Lett2021;520:132-42

[244] Walf-Vorderwülbecke V,Brooks T.Targeting acute myeloid leukemia by drug-induced c-MYB degradation.Leukemia2018;32:882-9

[245] Smith C,Simonin M.Harnessing the MYB-dependent TAL1 5’super-enhancer for targeted therapy in T-ALL.Mol Cancer2023;22:12 PMCID:PMC9847025

[246] Hu T,Cai B,Lu S.DNA methyltransferase 1-mediated CpG methylation of the miR-150-5p promoter contributes to fibroblast growth factor receptor 1-driven leukemogenesis.J Biol Chem2019;294:18122-30 PMCID:PMC6885633

[247] Daniel JP,Da Silva EL.Anticancer potential of mebendazole against chronic myeloid leukemia: in silico and in vitro studies revealed new insights about the mechanism of action.Front Pharmacol2022;13:952250 PMCID:PMC9452629

[248] Sakka L,Chalus M.Assessment of citalopram and escitalopram on neuroblastoma cell lines: cell toxicity and gene modulation.Oncotarget2017;8:42789-807 PMCID:PMC5522106

[249] Zhuo C,Hou W.Surprising anticancer activities of psychiatric medications: old drugs offer new hope for patients with brain cancer.Front Pharmacol2019;10:1262 PMCID:PMC6817617

[250] Sumitani K,Nagumo M.Cytotoxic effect of sodium nitroprusside on cancer cells: involvement of apoptosis and suppression of c-myc and c-myb proto-oncogene expression.Anticancer Res1997;17:865-71

[251] Magrinat G,Shami PJ.Nitric oxide modulation of human leukemia cell differentiation and gene expression.Blood1992;80:1880-4